Generics

Tetrabenazine tablets, 12.5 mg and 25 mg, had a market value of roughly $119 million in the 12 months ended July 2019, according to IQVIA.

Cyanocobalamin injection had a market value of approximately $70.2 million for the 12 months ended June 2019, according to IQVIA.

The Emend for injection brand had a market value of $279 million for the most recent 12 months ending in July 2019, according to IQVIA.

Patients have lost nearly $10 billion in potential biosimilar savings since 2015 due to delayed launches, according to a new white paper from the Biosimilars Council, a division of the Association for Accessible Medicines.

Fosaprepitant had a market value of roughly $279 million, according to IQVIA.

Olux-E Foam, 0.05% had a market value of approximately $11.1 million, for the 12 month period ended July 2019, according to IQVIA.

The decitabine brand and generics have a market value of over $91 million, while fosaprepitant has a brand market of approximately $279 million for the latest 12-month period.

The Zyban brand and generic had a market value of approximately $5.4 million for the most recent 12 months, ended June 2019.